실적분석 Agilent Technologies ($A) FY2026 Q3 Earnings Analysis — Revenue and Adjusted EPS Both Beat, Full-Year Guidance Raised
Earnings Scorecard
Revenue: $1.878 billion (+8.1% year-over-year, vs. $1.841 billion estimate) ✅ Beat
EPS: $1.62 adjusted (vs. $1.49 estimate, including $0.06 net tariff refund benefit) ✅ Beat
Guidance: Raised — FY2026 revenue of $7.49–$7.51 billion and adjusted EPS of $6.18–$6.21 (midpoint raised by $0.15 vs. prior outlook)
Stock Reaction: +3.84% after-hours ($161.04) — as of 06:00 KST, 08-27
What Went Well
Revenue beat: $1.878 billion, up 8.1% year-over-year
Life Sciences growth: Life Sciences & Diagnostics segment revenue of $746 million (+11%)
Guidance raised: Full-year revenue and adjusted EPS outlooks both lifted
Agilent, which makes analytical and clinical lab equipment, saw growth across all three segments. Life Sciences & Diagnostics led the overall pace, and the company emphasized that improvements in its operating system translated into margin expansion.
What Fell Short
Tariff refund tailwind: $0.06 of the $1.62 adjusted EPS came from a net refund benefit
CrossLab slowdown: Core revenue growth in the CrossLab segment, which handles consumables and services, came in at just 5%
No Q4 refund assumed: Next-quarter guidance does not include additional tariff refunds
Since the one-time refund boosted earnings and margins, the underlying core numbers excluding it will be key. The relatively slower pace in CrossLab, which covers consumables and services, is another point to watch in the next quarter.
What Management Said
CEO Padraig McDonnell said the cumulative impact of strategy execution and the Ignite operating system flowed through to Q3 results. He expressed confidence in the raised outlook, citing improving end markets and recovering demand in key regions.
Market Reaction and What to Watch Next
The combination of an earnings beat and a raised full-year outlook drew buying interest after the close.
Whether core margins excluding tariff refunds hold up in Q4
Whether double-digit growth in Life Sciences & Diagnostics continues
Whether core revenue growth in the CrossLab segment reaccelerates
Disclaimer: This content is for informational purposes only and does not constitute investment advice. All investment responsibility lies with the investor.
오늘의 AI 픽 5종목, 무료로 전부 공개합니다